Publication

Ibrutinib and obinutuzumab in CLL: improved MRD response rates with substantially enhanced MRD depletion for patients with > 1 year prior ibrutinib exposure

Rawstron, A
; 
Munir, T
; 
Brock, K
; 
Webster, N
; 
Vicente, M
; 
Yates, F
; 
Cramp, S
; 
Bishop, R
; 
Dalal, S
; 
De Tute, M
... show 8 more
Citations
Altmetric:
Abstract
Authors
Rawstron, A
Munir, T
Brock, K
Webster, N
Vicente, M
Yates, F
Cramp, S
Bishop, R
Dalal, S
De Tute, M
Sheehy, O
Pettitt, A
Fox, P
Devereux, S
Fegan, C
Macdonald, D
Bloor, Adrian
Hillmen, P
Affiliation
Department of Hematology and Medical Oncology, Emory University, Atlanta, GA
Description
Date
2018
Publisher
Collections
All Christie Publications
Show all metadata
Keywords
Type
Meetings and Proceedings
Citation
Rawstron A, Munir T, Brock K, Webster N, Vicente S, Yates F, et al. Ibrutinib and Obinutuzumab in CLL: Improved MRD Response Rates with Substantially Enhanced MRD Depletion for Patients with > 1 Year Prior Ibrutinib Exposure. Blood. 2018;132.
Journal Title
Journal ISSN
Volume Title
URI
http://hdl.handle.net/10541/621671
Embedded videos